Therapeutic effects of piperacillin/tazobactam combined with acetylcysteine solution on severe pneumonia after cerebral infarction
10.11816/cn.ni.2025-246942
- VernacularTitle:哌拉西林/他唑巴坦联合乙酰半胱氨酸溶液对脑梗死后并发重症肺炎的治疗效果
- Author:
Yongfei ZHU
1
;
Qinqin WANG
;
Wenzheng XU
;
Haichang LI
Author Information
1. 榆林市星元医院临床药学室,陕西 榆林 719000
- Publication Type:Journal Article
- Keywords:
Cerebral infarction;
Severe pneumonia;
Piperacillin/tazobactam;
Acetylcysteine solution;
Cardiopul-monary function;
Neurological function
- From:
Chinese Journal of Nosocomiology
2025;35(15):2258-2262
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the effects of piperacillin/tazobactam combined with acetylcysteine solution on severe pneumonia after cerebral infarction,and to analyze its impact on cardiopulmonary and neurological function.METHODS A total of 86 patients with severe pneumonia after cerebral infarction admitted to Yulin Xingyuan Hos-pital from Jan.2022 to Jun.2024 were selected and divided into a control group and a study group using the ran-dom number table method(single blind),with 43 cases in each group.The control group was treated with intrave-nous drip of piperacillin/tazobactam,while the study group received additional inhalation of acetylcysteine solution based on the control group's treatment.The levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)and procalcitonin(PCT)],lung function indicators[forced vital capacity(FVC),peak expiratory flow rate(PEF),forced expiratory volume in one second(FEV1)and mean maximal expiratory flow rate(MMEF)],cardiac function indicators[left ventricular ejection fraction(LVEF),cardiac output(CO),cardiac index(CI)and stroke volume(SV)],NIH Stroke Scale(NIHSS)score,clinical efficacy,and the occurrence of adverse reactions were compared before and after treatment.RESULTS Compared with the control group,the study group had low levels of CRP,IL-6,PCT and NIHSS scores after treatment(P<0.05),and high levels of FVC,PEF,FEV1,MMEF,LVEF,CO,CI,and SV after treatment(P<0.05).The overall response rate in the study group was 95.35%,higher than 81.40%in the control group(χ2=4.074,P=0.044).There was no statistically significant difference in the incidence of adverse reactions between the control group and the study group during treatments(χ2=0.179,P=0.672).CONCLUSION Piperacillin/tazobactam combined with inhaled acetylcysteine solution for the treatment of severe pneumonia after cerebral infarction can improve clinical efficacy,reduce levels of inflamma-tory factors,and enhance cardiopulmonary and neurological functions in patients,which has a high safety profile.
